logo
Share SHARE
FONT-SIZE Plus   Neg

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
American Airlines Group said pilots at its subsidiaries American Airlines and US Airways, represented by Allied Pilots Association, have approved a new five-year contract which provides immediate pay raises of 23 percent and subsequent annual raises of three percent for the next five years. LEGO Group, TT Games and Warner Bros. Interactive Entertainment have announced their 2015 slate of video games, including LEGO Jurassic World, LEGO Marvel's Avengers, and as well as new hand-held and mobile titles. Social-networking giant Facebook, Inc. is said to be testing their new 'Place Tips' feature for iOS users that will rival a similar service being provided by Yelp or Foursquare. The feature will provide the user relevant content about their location as long as they are there through pop ups on their news feed page of Facebook.
comments powered by Disqus
Follow RTT